Safety and efficacy of 5-aminolevulinic acid phosphate/iron in mild-to-moderate coronavirus disease 2019: A randomized exploratory phase II trial.
Tanaka T, Tashiro M, Ota K, Fujita A, Sawai T, Kadota J, Fukuda Y, Sumiyoshi M, Ide S, Tachikawa N, Fujii H, Hibino M, Shiomi H, Izumida M, Matsui K, Yamauchi M, Takahashi K, Yamanashi H, Sugimoto T, Akabame S, Umeda M, Shimizu M, Hosogaya N, Kosai K, Takeda K, Iwanaga N, Ashizawa N, Hirayama T, Takazono T, Yamamoto K, Imamura Y, Miyazaki T, Kobayashi Y, Ariyoshi K, Mukae H, Yanagihara K, Kita K, Izumikawa K.
Tanaka T, et al. Among authors: ide s.
Medicine (Baltimore). 2023 Aug 25;102(34):e34858. doi: 10.1097/MD.0000000000034858.
Medicine (Baltimore). 2023.
PMID: 37653769
Free PMC article.
Clinical Trial.